Gastroesophageal Cancer
88
19
32
31
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
19 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.6%
12 terminated out of 88 trials
72.1%
-14.4% vs benchmark
6%
5 trials in Phase 3/4
61%
19 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (88)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Supportive Oncology Care At Home RCT
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
PRO1107 in Patients With Advanced Solid Tumors
A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
Sample Collection for Ongoing Research and Product Evaluation Study